S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:CRDL

Cardiol Therapeutics (CRDL) Stock Price, News & Analysis

$1.81
+0.01 (+0.56%)
(As of 03/28/2024 ET)
Today's Range
$1.74
$1.90
50-Day Range
$1.02
$2.06
52-Week Range
$0.45
$2.17
Volume
228,349 shs
Average Volume
387,179 shs
Market Capitalization
$123.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Cardiol Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
65.7% Upside
$3.00 Price Target
Short Interest
Healthy
0.44% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.98mentions of Cardiol Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.34 out of 5 stars

Medical Sector

562nd out of 938 stocks

Biological Products, Except Diagnostic Industry

93rd out of 149 stocks

CRDL stock logo

About Cardiol Therapeutics Stock (NASDAQ:CRDL)

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19, as well as for the treatment of recurrent pericarditis and acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.

CRDL Stock Price History

CRDL Stock News Headlines

Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Cardiol Therapeutics Inc Class A CRDL
See More Headlines
Receive CRDL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardiol Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
3/29/2024
Next Earnings (Estimated)
5/17/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CRDL
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.00
High Stock Price Target
$3.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+65.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-23,790,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$60,000.00
Book Value
$0.63 per share

Miscellaneous

Free Float
64,590,000
Market Cap
$123.39 million
Optionable
Not Optionable
Beta
1.00
7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

  • Mr. David G. Elsley MBA
    President, CEO & Director
  • Mr. Christopher J. Waddick C.A.
    C.M.A., CPA, CMA, MBA, CFO, Corporate Secretary & Director
  • Mr. Bernard Lim B.Sc.
    Chief Operating Officer
  • Dr. Andrew Warwick Hamer M.D. (Age 62)
    Chief Medical Officer & Head of Research & Development
    Comp: $366.2k
  • Trevor Burns
    Investor Relations

CRDL Stock Analysis - Frequently Asked Questions

Should I buy or sell Cardiol Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cardiol Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CRDL shares.
View CRDL analyst ratings
or view top-rated stocks.

What is Cardiol Therapeutics' stock price target for 2024?

2 brokerages have issued 1-year price objectives for Cardiol Therapeutics' shares. Their CRDL share price targets range from $3.00 to $3.00. On average, they predict the company's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 65.7% from the stock's current price.
View analysts price targets for CRDL
or view top-rated stocks among Wall Street analysts.

How have CRDL shares performed in 2024?

Cardiol Therapeutics' stock was trading at $0.8432 at the beginning of the year. Since then, CRDL shares have increased by 114.7% and is now trading at $1.81.
View the best growth stocks for 2024 here
.

Are investors shorting Cardiol Therapeutics?

Cardiol Therapeutics saw a decrease in short interest in March. As of March 15th, there was short interest totaling 273,000 shares, a decrease of 24.4% from the February 29th total of 361,100 shares. Based on an average trading volume of 363,100 shares, the short-interest ratio is currently 0.8 days. Currently, 0.4% of the company's shares are sold short.
View Cardiol Therapeutics' Short Interest
.

When is Cardiol Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 17th 2024.
View our CRDL earnings forecast
.

How were Cardiol Therapeutics' earnings last quarter?

Cardiol Therapeutics Inc. (NASDAQ:CRDL) released its quarterly earnings data on Tuesday, November, 14th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.02.

Who are Cardiol Therapeutics' major shareholders?

Cardiol Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include AdvisorShares Investments LLC (1.82%), AXS Investments LLC (1.07%), Citadel Advisors LLC (0.00%), Concourse Financial Group Securities Inc. (0.00%) and Simplex Trading LLC (0.00%).

How do I buy shares of Cardiol Therapeutics?

Shares of CRDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CRDL) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners